. 2021 Jan 12;5(2):e523. doi: 10.1097/HS9.0000000000000523

Table 2.

Treatment of Stage I/II Disease.

Treatment	Stage	No. Patients (n)	Response (%)	PFS (%)	OS (%)	Grade 3/4 Toxicity (%)	References
Radiotherapy 50-56 Gy	I low risk	298	NA	5-y 79	5-y 89	NA	Yang et al⁵
2/3 DeVIC + 50 Gy radiotherapy	I/II	33	CR 77	5-y 63	5-y 70	Neutropenia 93	Yamaguchi et al³³
						Infection/febrile neutropenia 15
						TRM 0
2/3 DeVIC + 50 Gy radiotherapy	I/II	150	NA	5-y 61	5-y 72	Neutropenia NA	Yamaguchi et al³⁴
						Infection/febrile neutropenia 22
						TRM 0
Cisplatin + 45 Gy radiotherapy + 2 VIDL	I/II	30	CR 87	5-y 60	5-y 73	Neutropenia 80	Kim et al³⁵
						Infection/febrile neutropenia 17
						TRM 0
Cisplatin + 45 Gy radiotherapy + 2 MIDLE	I/II	28	CR 82	3-y 74	3-y 82	Neutropenia 91	Yoon et al³⁷
						Infection/febrile neutropenia 44
						TRM 4
Cisplatin + 45 Gy radiotherapy + 3 VIDP	I/II	30	CR 80	3-y 80	3-y 86	Neutropenia 47	Kim et al³⁶
						Infection/febrile neutropenia 15
						TRM 7
SMILE + > 40 Gy radiotherapy	I/II	17	CR 69	NA	NA	Neutropenia 67	Kwong et al³⁸
						Infection/febrile neutropenia 31
						TRM 6
mSMILE + 45 Gy radiotherapy	I/II	11	NA	2-y 83	2-y 100	NA	Qi et al³⁹
GELOX + 56 Gy radiotherapy	I/II	27	CR 74	2-y 86	2-y 86	Neutropenia 33	Wang et al⁴⁰
						Infection NA
						TRM 0

CR = complete remission; DeVIC = dexamethasone, etoposide, ifosfamide, and carboplatin; GELOX = gemcitabine, oxaliplatin, and L-asparaginase; MIDLE = methotrexate, ifosfamide, dexamethasone, L-asparaginase, and etoposide; mSMILE = dexamethasone, methotrexate, ifosfamide, PEG-asparginase; NA = not available; OS = overall survival; PFS = progression-free survival; SMILE = dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide; TRM = treatment-related mortality; VIDL = etoposide, ifosfamide, dexamethasone, and L-asparaginase; VIDP = etoposide, ifosfamide, dexamethasone, L-asparaginase.